Figure 9. Profiling the impact of a clinically relevant glucocortoid, budesonide (3 mg/kg) and two structurally distinct IKK-2 inhibitors GSK 657311A (100 mg/kg) and TPCA-1 (30 mg/kg) in CS-induced airway inflammation.

Vehicle or compound was orally dosed to the mice one hour prior to the morning CS challenge and one hour after the afternoon CS challenge. BALF samples were collected 20 hours after the last CS challenge. Figures A and C represent the levels of KC in the BALF and Figures B and D the BALF neutrophilia. Data are presented as mean ± s.e.m. of n = 6–8 observations. # indicates a statistically significant difference (p<0.05) from the air challenged control groups (Mann-Whitney test). * indicates statistical significance (p<0.05) from CS challenged vehicle dosed control groups by Kruskal-Wallis one-way-ANOVA with Dunn's multiple comparison post-hoc test. Bars with no annotation were not significantly different from their respective control group.